The acquisition includes Nimble's investigational candidate, an oral peptide IL23R inhibitor to treat psoriasis.

The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and ...

AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a ...

As AbbVie Ireland’s new general manager, Dana Kendall will oversee the company’s commercial business in the country.

Pfizer's shares have significantly underperformed, but the current valuation and high dividend yield present a compelling ...

The CHMP's opinion is based on late-stage data, which show that LLY's Omvoh is effective in Crohn's disease patients with or ...

Dermatology specialist Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to ...

This highly anticipated drug is expected to become a key treatment for prurigo nodularis and atopic dermatitis. Galderma’s midterm targets for the period 2023 to 2027 are for low- to mid-teens ...

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

Crain's restaurants reporter Ally Marotti talks with host Amy Guth about how a Chicago meat supplier is using AI to cut down ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the appointment of Isabel Kalofonos as Chief Commercial ...

Booking.com, the online travel platform, has contradicted a senior Ryanair executive who alleged that he had seen evidence of ...